JP2023510604A5 - - Google Patents
Info
- Publication number
- JP2023510604A5 JP2023510604A5 JP2022543411A JP2022543411A JP2023510604A5 JP 2023510604 A5 JP2023510604 A5 JP 2023510604A5 JP 2022543411 A JP2022543411 A JP 2022543411A JP 2022543411 A JP2022543411 A JP 2022543411A JP 2023510604 A5 JP2023510604 A5 JP 2023510604A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- acryloylpiperidine
- phenoxyphenyl
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025155610A JP2026001038A (ja) | 2020-01-20 | 2025-09-19 | 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062963238P | 2020-01-20 | 2020-01-20 | |
| US62/963,238 | 2020-01-20 | ||
| US202062970502P | 2020-02-05 | 2020-02-05 | |
| US62/970,502 | 2020-02-05 | ||
| US202063013895P | 2020-04-22 | 2020-04-22 | |
| US63/013,895 | 2020-04-22 | ||
| PCT/US2021/013883 WO2021150476A1 (en) | 2020-01-20 | 2021-01-19 | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025155610A Division JP2026001038A (ja) | 2020-01-20 | 2025-09-19 | 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510604A JP2023510604A (ja) | 2023-03-14 |
| JP2023510604A5 true JP2023510604A5 (https=) | 2024-01-26 |
Family
ID=74626161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022543411A Pending JP2023510604A (ja) | 2020-01-20 | 2021-01-19 | 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 |
| JP2025155610A Pending JP2026001038A (ja) | 2020-01-20 | 2025-09-19 | 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025155610A Pending JP2026001038A (ja) | 2020-01-20 | 2025-09-19 | 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11969418B2 (https=) |
| EP (1) | EP4093397A1 (https=) |
| JP (2) | JP2023510604A (https=) |
| KR (1) | KR20220130179A (https=) |
| CN (1) | CN115348862A (https=) |
| AU (1) | AU2021209608A1 (https=) |
| BR (1) | BR112022014058A2 (https=) |
| CA (1) | CA3168146A1 (https=) |
| IL (1) | IL294560A (https=) |
| MX (1) | MX2022008875A (https=) |
| TW (1) | TWI883107B (https=) |
| WO (1) | WO2021150476A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022014058A2 (pt) | 2020-01-20 | 2022-09-13 | Genzyme Corp | Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms) |
| AU2021398051A1 (en) * | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| EP4328226A4 (en) * | 2021-04-23 | 2025-08-27 | Hangzhou Solipharma Co Ltd | CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF |
| CN117412749A (zh) * | 2021-05-21 | 2024-01-16 | 杭州领业医药科技有限公司 | Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途 |
| WO2022257845A1 (zh) * | 2021-06-11 | 2022-12-15 | 苏州科睿思制药有限公司 | Tolebrutinib的晶型及其制备方法和用途 |
| WO2023280132A1 (zh) * | 2021-07-06 | 2023-01-12 | 苏州晶云药物科技股份有限公司 | 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法 |
| CA3260159A1 (en) * | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis |
| EP4601647A1 (en) * | 2022-10-11 | 2025-08-20 | Principia Biopharma Inc. | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
| AU2023408758A1 (en) * | 2022-12-20 | 2025-07-31 | Principia Biopharma Inc. | Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one |
| JP2026505764A (ja) | 2023-02-01 | 2026-02-18 | プリンシピア バイオファーマ インコーポレイテッド | 多発性硬化症を診断及び治療する方法 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| CA2465328C (en) | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| CN101056877B (zh) | 2004-09-14 | 2010-06-09 | 诺华疫苗和诊断公司 | 咪唑并喹啉化合物 |
| AU2006213746A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
| EP2700638A1 (en) | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| TW200911803A (en) | 2007-07-16 | 2009-03-16 | Organon Nv | 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| TWI500617B (zh) | 2010-05-31 | 2015-09-21 | Ono Pharmaceutical Co | Purine ketone derivatives |
| CN103502249A (zh) | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 |
| PL2710005T3 (pl) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
| US9199997B2 (en) | 2011-11-29 | 2015-12-01 | Ono Pharmaceutical Co., Ltd. | Purinone derivative hydrochloride |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| WO2013191965A1 (en) | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| SI2892900T1 (en) | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| EA201590855A1 (ru) | 2012-11-15 | 2015-11-30 | Фармасайкликс, Инк. | Соединения пирролопиримидина как ингибиторы киназ |
| US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| KR102196882B1 (ko) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Hdm2 억제제로서의 치환된 이미다조피리딘 |
| MX365640B (es) | 2012-12-21 | 2019-06-10 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones. |
| WO2015132799A2 (en) | 2014-02-03 | 2015-09-11 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| US10253023B2 (en) | 2014-10-06 | 2019-04-09 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| UA124090C2 (uk) | 2015-06-03 | 2021-07-21 | Прінсіпіа Байофарма Інк. | Інгібітори тирозинкінази |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| EP3414234B1 (en) | 2015-10-14 | 2022-06-29 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| SI3377484T1 (sl) | 2015-11-17 | 2024-02-29 | Merck Patent Gmbh | Postopki za zdravljenje multiple skleroze z uporabo pirimidinskih in piridinskih spojin z btk inhibitorno aktivnostjo |
| BR112022014058A2 (pt) | 2020-01-20 | 2022-09-13 | Genzyme Corp | Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms) |
| WO2022081512A1 (en) | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
| AU2021398051A1 (en) | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| EP4328226A4 (en) | 2021-04-23 | 2025-08-27 | Hangzhou Solipharma Co Ltd | CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF |
-
2021
- 2021-01-19 BR BR112022014058A patent/BR112022014058A2/pt unknown
- 2021-01-19 CN CN202180009557.XA patent/CN115348862A/zh active Pending
- 2021-01-19 US US17/151,954 patent/US11969418B2/en active Active
- 2021-01-19 EP EP21705735.5A patent/EP4093397A1/en active Pending
- 2021-01-19 IL IL294560A patent/IL294560A/en unknown
- 2021-01-19 KR KR1020227028409A patent/KR20220130179A/ko active Pending
- 2021-01-19 MX MX2022008875A patent/MX2022008875A/es unknown
- 2021-01-19 TW TW110101887A patent/TWI883107B/zh active
- 2021-01-19 AU AU2021209608A patent/AU2021209608A1/en active Pending
- 2021-01-19 WO PCT/US2021/013883 patent/WO2021150476A1/en not_active Ceased
- 2021-01-19 CA CA3168146A patent/CA3168146A1/en active Pending
- 2021-01-19 JP JP2022543411A patent/JP2023510604A/ja active Pending
-
2024
- 2024-03-22 US US18/613,641 patent/US20240366585A1/en active Pending
-
2025
- 2025-09-19 JP JP2025155610A patent/JP2026001038A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510604A5 (https=) | ||
| CN106456626B (zh) | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 | |
| CA2856646C (en) | Combination treatment of cancer | |
| ES2674947T3 (es) | Terapia combinada para el tratamiento de la esclerosis múltiple | |
| JP2023088944A5 (https=) | ||
| JP2013516493A5 (https=) | ||
| JP2022502492A5 (https=) | ||
| JP2024178420A5 (https=) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP5837877B2 (ja) | 静脈内投与イブプロフェンを用いた患者の治療 | |
| EP1383495A1 (en) | Duloxetine for treatment of hot flashes | |
| TW202341997A (zh) | 用於治療腸胃疾病或病狀之神經活性類固醇 | |
| JP2011506607A5 (https=) | ||
| JP2024506385A5 (https=) | ||
| AU2013362755A1 (en) | Uses and methods for the treatment of liver diseases or conditions | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| JP2024518804A5 (https=) | ||
| CN101467992A (zh) | L-肉碱用于治疗心血管疾病的用途 | |
| JP2024501235A5 (https=) | ||
| CA2687013A1 (en) | Method and composition for treatment and prevention of broad spectrum virus ailments | |
| JP2021121603A (ja) | 多発性硬化症を処置するための併用療法 | |
| TW202216145A (zh) | 伴隨代謝異常之疾病或症候群中的肌力低下症狀之改善劑或預防劑 | |
| EP1448189A2 (en) | Use of bisindolmaleimide and gemcitabine for the treatment of cancer | |
| HK1247106A1 (zh) | 逼尿肌过度活动伴收缩功能受损的改善剂 | |
| JP2022540917A5 (https=) |